Korean Circulation Journal

  • 제48권9호
  • /
  • Pages.839-853
  • /
  • 2018
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension

  • Kim, Kyung-Hee (Division of Cardiology, Department of Internal Medicine, Sejong General Hospital) ;
  • Kim, Hyung-Kwan (Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Chan, Stephen Y. (Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh Medical Center (UPMC) and University of Pittsburgh School of Medicine) ;
  • Kim, Yong-Jin (Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Sohn, Dae-Won (Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul National University College of Medicine)
  • 투고 : 2017.11.12
  • 심사 : 2018.03.14
  • 발행 : 2018.09.30
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Objectives: Macitentan (MAC) reduces morbidity and mortality among advanced-stage pulmonary arterial hypertension (PAH) patients. However, data regarding the histopathologic and hemodynamic benefits of MAC treatment at an early stage of PAH is lacking. Methods: One week after monocrotaline (MCT) injection, rats were randomly assigned to MAC (n=16), MAC combined with sildenafil (SIL) (MAC+SIL, n=16), or normal saline (MCT, n=16). Twelve sham rats (Sham) were included for comparison. Right ventricular (RV) systolic function was assessed via echocardiography as the RV fractional area change (RV-FAC). An invasive pressure-volume analysis using a Millar conductance catheter was performed 7 weeks after MCT injection. Rats were subsequently euthanized for histopathologic analysis. Results: RV-right atrial pressure gradient on echocardiography was significantly increased 3 weeks after MCT injection, but was maintained in the Sham. RV-FAC was less deteriorated in the MAC, compared to that in the MCT ($44{\pm}3%$ vs. $25{\pm}7%$, p<0.05), and the co-administration of SIL showed no additional benefit ($45{\pm}8%$, p>0.05 vs. the MAC). On invasive hemodynamic analyses, RV end-systolic ($196{\pm}78{\mu}L$) and end-diastolic volumes ($310{\pm}86{\mu}L$), pulmonary artery systolic pressure ($89{\pm}7.2mmHg$), and end-systolic pressure-volume relationship ($-254{\pm}25.1$) were significantly worse in the MCT vs. in the MAC ($101{\pm}45{\mu}L$, $235{\pm}55{\mu}L$, $40{\pm}10.5mmHg$, and $-145{\pm}42.1$, respectively) and MAC+SIL ($109{\pm}47{\mu}L$, $242{\pm}46{\mu}L$, $38{\pm}9.2mmHg$, and $-151{\pm}39.2$, respectively) (all p<0.05). However, the MAC and MAC+SIL did not differ (all p>0.05). On histopathology, both RV and lung fibrosis were significantly reduced in the MAC and MAC+SIL vs. in the MCT (all p<0.05); the 2 treatment groups did not differ. Conclusions: MAC treatment at an earlier stage significantly attenuated experimental PAH progression hemodynamically and histopathologically.

키워드

과제정보

연구 과제 주관 기관 : Korea Society of Echocardiography

참고문헌

  1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67-119. https://doi.org/10.1093/eurheartj/ehv317
  2. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63. https://doi.org/10.1161/CIRCULATIONAHA.109.911818
  3. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011;8:443-55. https://doi.org/10.1038/nrcardio.2011.87
  4. Nogueira-Ferreira R, Vitorino R, Ferreira R, Henriques-Coelho T. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: a network approach. Pulm Pharmacol Ther 2015;35:8-16. https://doi.org/10.1016/j.pupt.2015.09.007
  5. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100. https://doi.org/10.1016/S0140-6736(08)60919-8
  6. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809-18. https://doi.org/10.1056/NEJMoa1213917
  7. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57. https://doi.org/10.1056/NEJMoa050010
  8. Kim KH, Kim YJ, Ohn JH, et al. Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity. Circulation 2012;125:1390-401. https://doi.org/10.1161/CIRCULATIONAHA.111.065300
  9. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214-22. https://doi.org/10.1038/nm1175
  10. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-32. https://doi.org/10.1152/ajplung.00217.2009
  11. Baber SR, Deng W, Master RG, et al. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol 2007;292:H1120-8. https://doi.org/10.1152/ajpheart.00173.2006
  12. Hessel MH, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol 2006;291:H2424-30. https://doi.org/10.1152/ajpheart.00369.2006
  13. Ding M, Lei J, Qu Y, et al. Calorie restriction attenuates monocrotaline-induced pulmonary arterial hypertension in rats. J Cardiovasc Pharmacol 2015;65:562-70. https://doi.org/10.1097/FJC.0000000000000224
  14. Iglarz M, Bossu A, Wanner D, et al. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci 2014;118:333-9. https://doi.org/10.1016/j.lfs.2014.02.018
  15. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736-45. https://doi.org/10.1124/jpet.108.142976
  16. Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood) 2006;231:967-73.
  17. Kim KH, Kim YJ, Lee SP, et al. Survival, exercise capacity, and left ventricular remodeling in a rat model of chronic mitral regurgitation: serial echocardiography and pressure-volume analysis. Korean Circ J 2011;41:603-11. https://doi.org/10.4070/kcj.2011.41.10.603
  18. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15. https://doi.org/10.1136/ard.2009.114264
  19. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-7. https://doi.org/10.1164/rccm.200806-953OC
  20. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. https://doi.org/10.1056/NEJMoa012212
  21. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35. https://doi.org/10.1016/j.jacc.2005.04.050
  22. Iglarz M, Landskroner K, Bauer Y, et al. Comparison of macitentan and bosentan on right ventricular remodeling in a rat model of non-vasoreactive pulmonary hypertension. J Cardiovasc Pharmacol 2015;66:457-67. https://doi.org/10.1097/FJC.0000000000000296
  23. Bruderer S, Hopfgartner G, Seiberling M, et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica 2012;42:901-10. https://doi.org/10.3109/00498254.2012.664665
  24. Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;373:834-44. https://doi.org/10.1056/NEJMoa1413687

피인용 문헌

  1. The Role of G Protein-Coupled Receptors in the Right Ventricle in Pulmonary Hypertension vol.5, pp.None, 2018, https://doi.org/10.3389/fcvm.2018.00179
  2. Novel Targets in a High-Altitude Pulmonary Hypertension Rat Model Based on RNA-seq and Proteomics vol.8, pp.None, 2018, https://doi.org/10.3389/fmed.2021.742436